Clinical Trial Update: Expanded Access to Tipifarnib

View source ↗

Summary

Kura Oncology announced expanded access to Tipifarnib for patients with HRAS mutations or Peripheral T-Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) | Status: AVAILABLE